Clinical trials
HIV Infected Individuals clinical trials
Below are recruiting hiv infected individuals clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07584122Recruiting
Increasing HIV Prevention Access in Rio de Janeiro
This study helps people at higher risk of HIV get access to PrEP, a daily medication that prevents HIV infection. The program focuses on underserved communities in Rio de Janeiro and aims to make PrEP easier to access and use.
Nova Iguaçu, Rio de JaneiroAges 15 years+ - NCT05075967Enrolling by invitation
Study attitudes and services among southern gay and bisexual men
This study gathers opinions and experiences from gay and bisexual men and from clinic staff in the American South. It helps researchers understand what affects HIV prevention and care, and how programs can better support people at higher risk.
Durham, North CarolinaAges 15 years+ - NCT06746701Recruiting
Peginterferon with NA to prevent liver cancer in hepatitis B
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
Guangzhou, GuangdongAges 18–65 - NCT04052022Recruiting
Study of TB flare-ups in people without HIV
This study looks at why some people with tuberculosis (TB) get worse or develop new inflammation after they initially start improving on treatment—called a “paradoxical reaction.” It collects blood and tissue samples to better understand these flare-ups and guide future care.
Bethesda, MarylandAges 18–99 - NCT05418868RecruitingPhase 1
Long-acting cabotegravir injection safety in healthy adults
This Phase 1 study tests how the body handles a long-acting (slow-release) cabotegravir injection combined with a drug called hyaluronidase. It also checks safety and side effects in healthy adults to help future HIV-prevention or treatment plans.
Orlando, FloridaAges 18–55 - NCT05515770RecruitingPhase 3
Injectable PrEP shot for HIV prevention in higher-risk adults
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Rio de JaneiroAges 18–30 - NCT05816083Recruiting
Virtual reality tool for teens and young adults after trauma
This study tests a virtual reality program to help young people who have been through serious violence or sexual assault (“ITE”). It’s also open to certain healthcare workers who support these young people.
Charleston, South CarolinaAges 15–30 - NCT06139224Recruiting
Gut Bacteria and Inflammation in HIV and Heavy Drinking
This study looks at how gut bacteria and inflammation interact in people with both HIV and heavy alcohol use. It aims to find new ways to improve health by understanding these connections.
Chicago, IllinoisAges 45–75 - NCT06665646RecruitingPhase 1
HIV vaccine booster study for previous trial participants
This study tests a booster vaccine for HIV in people who were part of an earlier HIV vaccine trial. The goal is to see if it's safe and helps the immune system fight HIV better.
San Francisco, CaliforniaAges 18–60 - NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07226323Recruiting
WeCare for mental health and medication adherence in South Africa
This trial tests a counselling program called WeCare to help men who have sex with men in Johannesburg stick to their HIV or PrEP medication and manage depression symptoms. It is designed for those who are struggling with adherence or have unsuppressed HIV.
JohannesburgAges 18 years+ - NCT06749054RecruitingPhase 2
Long-acting HIV treatment for teens and children with drug resistance
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
Atlanta, GeorgiaAges Up to 17 years - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT06507059RecruitingPhase 3
Injectable HIV treatment trial for people with unsuppressed virus
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
KeelungAges 18 years+ - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT04892654RecruitingPhase 3
Doravirine plus dolutegravir switch for people with HIV
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
LondonAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT06743204Recruiting
Testing for sexually transmitted infections in women at risk for HIV
This study tests if combining sexually transmitted infection (STI) testing with HIV prevention medication (PrEP) helps control the HIV epidemic. It is for sexually active women aged 15-39 who live in Rakai and recently participated in a community health survey.
KalisizoAges 15–39 - NCT07089836Recruiting
Syphilis blood test study for at-risk and healthy people
This study tests two new blood tests for syphilis. It compares them to approved tests using blood from people who may have or had syphilis, including pregnant women, HIV-positive people, and healthy volunteers.
Lancaster, CaliforniaAges 13 years+ - NCT07610772RecruitingPhase 1
Safety study of a new hepatitis B antibody for hepatitis D
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
AarhusAges 18–70 - NCT05856890RecruitingPhase 1
Test antibody treatment for chronic hepatitis B
This Phase 1 trial tests HepB mAb19, an antibody medicine, in adults with chronic hepatitis B. The goal is to see how it works and how safe it is in people whose hepatitis B is controlled on current antiviral treatment.
New York, New YorkAges 18–70 - NCT04319367RecruitingPhase 2
Antibody treatment added to HIV meds for early HIV
This Phase 2 trial tests whether adding long-acting HIV antibodies to standard HIV treatment (ART) can help control HIV in people who started ART soon after getting infected. It also checks how safe the antibody treatment is and how well it works over time.
AarhusAges 18–60 - NCT01386437Recruiting
Study immune problems and fungal infections
This study looks at how immune system problems relate to fungal infections, using medical records and lab tests on blood and tissue. It may help researchers understand the cause of these infections—especially for people with inherited immune conditions—and improve future care.
Bethesda, MarylandAges 1 day–99 years - NCT06306196RecruitingPhase 2
Hepatitis E vaccine study in healthy adults, children, and people with HIV
This study tests a hepatitis E vaccine called Hecolin in healthy people (ages 2–45) and in adults (18–45) living with HIV who are on antiviral treatment. It aims to see how well the vaccine works and if it's safe for different groups.
Ga-RankuwaAges 2–45
Hear when a new HIV Infected Individuals trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv infected individuals?
- Yes. Clin2 currently lists 72 recruiting hiv infected individuals studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv infected individuals trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv infected individuals trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.